The Anti-VEGF Aptamer Approach: The Macugen Collaborative Trial

November 16, 2003

Recent results of clinical trials of the anti-VEGF aptamer Macugen (pegaptanibsodium are extremely promising for patients with choroidal neovascularization,said Carmen Puliafito, MD, MBNA, chairman of the Bascom Palmer Eye Institute,Miami.